Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy.

Deweyert A, Iredale E, Xu H, Wong E, Schmid S, Hebb MO.

J Neurooncol. 2019 May;143(1):49-56. doi: 10.1007/s11060-019-03145-8. Epub 2019 Mar 9.

2.

Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.

Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, Gaillard PJ, Peter Vandertop W, Wesseling P, Noske D, Kaspers GJL, Hulleman E.

J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.

PMID:
28291423
3.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
4.

Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma.

Di Sebastiano AR, Deweyert A, Benoit S, Iredale E, Xu H, De Oliveira C, Wong E, Schmid S, Hebb MO.

Sci Rep. 2018 May 8;8(1):7301. doi: 10.1038/s41598-018-25639-7.

5.

Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.

Heiss JD, Jamshidi A, Shah S, Martin S, Wolters PL, Argersinger DP, Warren KE, Lonser RR.

J Neurosurg Pediatr. 2018 Dec 7;23(3):333-342. doi: 10.3171/2018.9.PEDS17225.

PMID:
30544335
6.

Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.

Sun Y, Sun Y, Yan K, Li Z, Xu C, Geng Y, Pan C, Chen X, Zhang L, Xi Q.

EBioMedicine. 2019 May 3. pii: S2352-3964(19)30282-8. doi: 10.1016/j.ebiom.2019.04.043. [Epub ahead of print]

7.

Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.

Carceller F, Fowkes LA, Khabra K, Moreno L, Saran F, Burford A, Mackay A, Jones DT, Hovestadt V, Marshall LV, Vaidya S, Mandeville H, Jerome N, Bridges LR, Laxton R, Al-Sarraj S, Pfister SM, Leach MO, Pearson AD, Jones C, Koh DM, Zacharoulis S.

J Neurooncol. 2016 Aug;129(1):109-21. doi: 10.1007/s11060-016-2151-8. Epub 2016 May 14.

PMID:
27180091
8.

Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).

Gwak HS, Park HJ.

Crit Rev Oncol Hematol. 2017 Dec;120:111-119. doi: 10.1016/j.critrevonc.2017.10.013. Epub 2017 Oct 31. Review.

PMID:
29198324
9.

In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.

Xu HU, Bihari F, Whitehead S, Wong E, Schmid S, Hebb MO.

Anticancer Res. 2016 Jan;36(1):71-80.

PMID:
26722029
10.

Pediatric diffuse intrinsic pontine glioma patients from a single center.

Kebudi R, Cakir FB, Agaoglu FY, Gorgun O, Ayan I, Darendeliler E.

Childs Nerv Syst. 2013 Apr;29(4):583-8. doi: 10.1007/s00381-012-1986-3. Epub 2012 Dec 8.

PMID:
23224361
11.

T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity.

Harward S, Harrison Farber S, Malinzak M, Becher O, Thompson EM.

Childs Nerv Syst. 2018 Mar;34(3):449-455. doi: 10.1007/s00381-017-3659-8. Epub 2017 Nov 18.

PMID:
29151166
12.

Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.

Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, Ballester LY, Nazarian J, Eberhart CG, Rodriguez FJ.

Acta Neuropathol Commun. 2014 Jun 3;2:59. doi: 10.1186/2051-5960-2-59.

13.

B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.

Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH, Souweidane MM.

J Neurooncol. 2013 Feb;111(3):257-64. doi: 10.1007/s11060-012-1021-2. Epub 2012 Dec 12.

14.

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.

Qi J, Esfahani DR, Huang T, Ozark P, Bartom E, Hashizume R, Bonner ER, An S, Horbinski CM, James CD, Saratsis AM.

Acta Neuropathol Commun. 2019 May 15;7(1):75. doi: 10.1186/s40478-019-0727-1.

15.

Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition.

Taylor IC, Hütt-Cabezas M, Brandt WD, Kambhampati M, Nazarian J, Chang HT, Warren KE, Eberhart CG, Raabe EH.

J Neuropathol Exp Neurol. 2015 Aug;74(8):778-90. doi: 10.1097/NEN.0000000000000216.

16.

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.

Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WG, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS.

Cancer Manag Res. 2018 Sep 12;10:3483-3500. doi: 10.2147/CMAR.S167095. eCollection 2018.

17.

Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.

Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devaney JM, Harmon B, Hall J, Raabe EH, An P, Weingart M, Rood BR, Magge SN, MacDonald TJ, Packer RJ, Nazarian J.

Acta Neuropathol. 2014;127(6):881-95. doi: 10.1007/s00401-013-1218-2. Epub 2013 Dec 3.

18.

Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma.

Zhang Y, Dong W, Zhu J, Wang L, Wu X, Shan H.

Cell Biosci. 2017 Oct 30;7:56. doi: 10.1186/s13578-017-0184-0. eCollection 2017.

19.

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.

Misuraca KL, Cordero FJ, Becher OJ.

Front Oncol. 2015 Jul 24;5:172. doi: 10.3389/fonc.2015.00172. eCollection 2015. Review.

20.

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C.

Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9.

Supplemental Content

Support Center